Contineum Therapeutics CTNM
NASDAQ CTNM
$13.12 +0.13 (+1.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Contineum Therapeutics (CTNM) Gains from Sales and Divestitures (2024 - 2025)

Updated

Contineum Therapeutics (CTNM) recorded Gains from Sales and Divestitures of $67,000 in Q3 2025, up 318.8% from $16,000 a year earlier.

Analysis

Contineum Therapeutics (CTNM) Gains from Sales and Divestitures (2024 - 2025) Analysis & Trends

For FY2024, Contineum Therapeutics reported Gains from Sales and Divestitures of $16,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Contineum Therapeutics 491.58 Mn 491.58 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 67,000.00
Mar 31, 2025 -67,000.00
Sep 30, 2024 16,000.00
API Access

Contineum Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CTNM&period=max&api_key=YOUR_API_KEY